We welcome paediatrician and general practitioner Susanne Ellfors Zetterlund as our new Chief Medical Officer. Throughout Susanne's professional life preventing disease before it occurs, has been the common thread. Vaccination is one of the most effective medical measures to prevent disease.
The first child has been vaccinated in The Gambia with the company's ETEC vaccine candidate, ETVAX®. It is a randomised, placebo-controlled, and double-blind phase IIb study. The study will include about 5,000 children aged 6-23 months. The overall goal of the study is to investigate the protective effect against moderate to severe diarrhoea caused by ETEC over a 1- to 2-year period.
Despite the corona pandemic, with all its challenges, we continue to grow and once more start the year by welcoming new colleagues. We are now further strengthening our organisation within manufacturing and are pleased to welcome Tomas Danielsson as the new Senior Project Manager.
The documentary, People We Come Across follows Scandinavian Biopharma’s vaccine study in Benin where more than 700 Finnish tourists travelled on a holiday as research volunteers. The documentary describes the interactions between the inhabitants of the fishing village of Grand Popo and the Finnish participants.
Scandinavian Biopharma continues to expand and strengthens the organisation by recruiting Catharina Forzelius to the new position as Program Director. As the Program Director Catharina will coordinate and lead the development and commercialisation programmes of the company’s ETEC vaccine candidate ETVAX®.
Scandinavian Biopharma strengthens the organization in Clinical Operations through the recruitment of the pharmacist Christin Hindrika Strid, as Clinical Operations Manager. The company is in a late-stage clinical development phase and has an ambitious clinical development programme with several ongoing clinical studies for the ETEC vaccine candidate ETVAX®.
Scandinavian Biopharma strengthens the organization in regulatory affairs through the recruitment of Åsa Dahlbäck as the new VP Regulatory Affairs. Åsa has more than 30 years of experience in the biotech industry and extensive knowledge of regulatory activities in biopharmaceutical products and biological drug development projects.
PDVAC will continue to advocate for and support the development of a ETEC vaccine and our vaccine candidate ETVAX® was described as the most advanced ETEC candidate with encouraging phase 2b study data.
Scandinavian Biopharma continues to expand and has recruiting Erika Söderström to the new position as Key Account Manager.
We are proud to announce that all participants have now received the third and final vaccination dose in our Phase 1 trial in Zambia. The completion of the enrolment in the Zambian study is another important milestone towards making a vaccine available for children in low- and middle-income countries. An ETEC-vaccine is prioritized by WHO.
Encouraging results from a Phase 2b study. The trial enrolled adult volunteers from Finland who travelled to Benin after receiving ETVAX® or placebo. The study results confirm the excellent safety and overall positive immunogenicity of ETVAX®, as well as a significant protective efficacy of 56% against all severe diarrhea, independent of pathogen.
Scandinavian Biopharma is now strengthening its organization by recruiting Anna Hill to the new position as Clinical Operations Manager. Anna will have the overall responsibility for the company's clinical development program and be responsible for ensuring that ongoing and future clinical trials are performed in a compliant and efficient manner.
Vi utvecklar det första vaccinet i världen mot diarré orsakad av ETEC för att skydda både barn och vuxna i endemiska länder och resenärer till högriskdestinationer.
Vi distribuerar ett brett sortiment av biologiska specialistläkemedel med fokus på vacciner och immunglobuliner.
www.scandinavianbiopharma.se
Vår information på mynewsdesk riktar sig till journalister och media.
